Anteris Technologies Global Corp. Common Stock
$8.42
$0.05 (+0.60%)
$8.35Day Range$8.60
Key Statistics
Market Cap
$820.60M
Shares Outstanding
97.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 13, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$8.50
Day High
$8.60
Day Low
$8.35
Volume
445.0K
VWAP
$8.43
Prev Close
$8.37
Transactions
--
Acc. Volume
--
About Anteris Technologies Global Corp. Common Stock
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIESSIC 3842174 employees860 BLUE GENTIAN ROAD, EAGAN, MN, 55121651-493-0606IPO Dec 13, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0002011514
- Composite FIGI
- BBG01PLXJNR7
- Share Class FIGI
- BBG01PLXJQ81
- Ticker Root
- AVR
- SIC Code
- 3842
About Anteris Technologies Global Corp. Common Stock (AVR) Stock
Anteris Technologies Global Corp. Common Stock (AVR) closed the 2026-09-17 session at $8.42, up 0.60% versus the previous close (+0.05). The stock opened at $8.50 and traded between $8.35 and $8.60 during that session. Session trading volume was 445K shares. The volume-weighted average price (VWAP) is $8.43.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
Anteris Technologies Global Corp. Common Stock has a market capitalization of $820.6 million. The company operates in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES industry classification. AVR is listed on the XNAS exchange. The company employs approximately 174 people. Anteris Technologies Global Corp. Common Stock is headquartered in EAGAN, MN. The recorded listing date is 2024-12-13.
On this page you can find market AVR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector.